Discussion
Health Canada has approved Boehringer Ingelheim‘s oral therapy Jascayd (nerandomilast) as a treatment for adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). “The authorization of JASCAYD marks an important milestone for patients, caregivers and healthcare professionals,” Rasha Eldesouky Abouelabbas, vice president of medical and…